JAC Advance Access published online on July 8, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh360
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Veterinary Laboratories Agency (Weybridge), New Haw, Addlestone, Surrey KT15 3NB, UK
* To whom correspondence should be addressed. E-mail: l.randall{at}vla.defra.gsi.gov.uk.
Objectives: To determine the mutant prevention concentrations (MPCs) of ciprofloxacin and enrofloxacin against four strains of Salmonella enterica serovar Enteritidis and four strains of S. Typhimurium including one fully susceptible, one multiply resistant (MAR), one GyrA mutant and one GyrA/MAR mutant. Further, to examine mutants arising after exposure to sub-MPC concentrations of the antibiotics for susceptibility to ciprofloxacin and enrofloxacin, and cyclohexane tolerance. Methods: MICs were determined using the agar dilution method of the BSAC. The MPC was recorded as the lowest concentration of antibiotic to inhibit growth from an inoculum of 1010 cfu. Results: The MPCs and resulting MPC/MIC ratios of enrofloxacin were generally two- to four-fold higher than for ciprofloxacin. At 24 h for both antibiotics, MPCs were lowest for the fully susceptible strains (0.25-0.5 mg/L), similar for the MAR (1-4 mg/L) and GyrA (2-4 mg/L) mutants and highest for the GyrA/MAR mutants (1-8 mg/L). MPC/MIC ratios at 24 h were 2-16 for all strains except those for the MAR strains without mutation in gyrA where the ratios were 8-64. Conclusions: The ability to eradicate Salmonella in vivo depends on many factors such as antibiotic susceptibility of the strain, dose and route of administration. It is suggested that these MPC values will be useful when considering dosing strategies. In view of the high MPC/MIC ratio, MAR strains with wild-type gyrA, although susceptible to ciprofloxacin (MICs 0.06-0.13 mg/L), may give rise to treatment failures.
Revised June 9, 2004
Accepted June 11, 2004
Brief report
Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica
2 Antimicrobial Agents Research Group, Division of Immunity and Infection, The Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J.-B. Michel, P. J. Yeh, R. Chait, R. C. Moellering Jr., and R. Kishony Drug interactions modulate the potential for evolution of resistance PNAS, September 30, 2008; 105(39): 14918 - 14923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kehrenberg, A. de Jong, S. Friederichs, A. Cloeckaert, and S. Schwarz Molecular mechanisms of decreased susceptibility to fluoroquinolones in avian Salmonella serovars and their mutants selected during the determination of mutant prevention concentrations J. Antimicrob. Chemother., May 1, 2007; 59(5): 886 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Randall, S. W. Cooles, N. C. Coldham, K. S. Stapleton, L. J. V. Piddock, and M. J. Woodward Modification of Enrofloxacin Treatment Regimens for Poultry Experimentally Infected with Salmonella enterica Serovar Typhimurium DT104 To Minimize Selection of Resistance Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4030 - 4037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Drlica, X. Zhao, J. M. Blondeau, and C. Hesje Low Correlation between MIC and Mutant Prevention Concentration Antimicrob. Agents Chemother., January 1, 2006; 50(1): 403 - 404. [Full Text] [PDF]
|
|
|
|
|
|
H.-G. Wetzstein Comparative Mutant Prevention Concentrations of Pradofloxacin and Other Veterinary Fluoroquinolones Indicate Differing Potentials in Preventing Selection of Resistance Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4166 - 4173. [Abstract] [Full Text] [PDF]
|
|